At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
Bevacizumab +1 moredrug
Likely dose
Bevacizumab 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
In Brief
A Phase 2 clinical trial evaluating Bevacizumab and Lapatinib for Brain Cancer and Pediatric Cancers. Completed, enrolled 24 participants across 6 sites.
Detailed Summary
The goal of this clinical research study is to learn if the combination of Avastin (bevacizumab) and Tykerb (lapatinib) can help to control ependymoma in pediatric patients. The safety of this drug combination will also be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain Cancer, Pediatric Cancers
CountriesUnited States
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2009
Enrollment StartJul 2009
Primary CompletionApr 2015
TodayJul 2026
First PostedApr 20, 2009
Enrollment StartJul 1, 2009
Primary CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 17.2 years ago
Interventions
Bevacizumabdrug
10 mg/kg given by vein over 90 minutes for first injection (30-60 minutes for subsequent doses) every 2 weeks while on study (2 times during each 4-week "study cycle").
Lapatinibdrug
Pills of 700 mg/m\^2/dose given orally 2 times each day.